Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2018 08:01 ET | Source: Calithera Biosciences, Inc.

Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)

Phase 2 to Continue Enrolling Colorectal Cancer Patients with PIK3CA Mutation SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical...
May 10, 2018 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights

-Initiated Randomized Phase 2 CANTATA Trial -Presented Preclinical Data at the American Association for Cancer Research SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Calithera...
April 25, 2018 16:03 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018

SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
April 18, 2018 07:01 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
April 13, 2018 08:02 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018

SOUTH SAN FRANCISCO, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
March 23, 2018 08:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at Needham & Company 17th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
March 08, 2018 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
March 06, 2018 08:01 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at Cowen & Company 38th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage biotechnology company focused on the development of novel cancer...
March 02, 2018 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Fourth Quarter 2017 Financial Results on Thursday, March 8, 2018

SOUTH SAN FRANCISCO, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
February 09, 2018 05:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Participate in Leerink Partners 7th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...